- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2012 (2012), Article ID 828139, 9 pages
Development of -N4-NIM for Molecular Imaging of Tumor Hypoxia
1Department of Experimental Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
2Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Received 31 January 2012; Revised 24 March 2012; Accepted 1 April 2012
Academic Editor: Yasuhisa Fujibayashi
Copyright © 2012 Mohammad S. Ali et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- B. C. Liang, “Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines,” Journal of Neuro-Oncology, vol. 29, no. 2, pp. 149–155, 1996.
- A. J. Giaccia, “Hypoxic stress proteins: survival of the fittest,” Seminars in Radiation Oncology, vol. 6, no. 1, pp. 46–58, 1996.
- T. G. Graeber, C. Osmanian, T. Jacks et al., “Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours,” Nature, vol. 379, no. 6560, pp. 88–91, 1996.
- S. Dai, M. L. Huang, C. Y. Hsu, and K. S. C. Chao, “Inhibition of hypoxia inducible factor 1α causes oxygen-independent cytotoxicity and induces p53 independent apoptosis in glioblastoma cells,” International Journal of Radiation Oncology Biology Physics, vol. 55, no. 4, pp. 1027–1036, 2003.
- J. M. Brown, “The hypoxic cell: a target for selective cancer therapy—eighteenth Bruce F. Cain Memorial Award Lecture,” Cancer Research, vol. 59, no. 23, pp. 5863–5870, 1999.
- T. Chu, R. Li, S. Hu, X. Liu, and X. Wang, “Preparation and biodistribution of technetium-99m-labeled 1-(2-nitroimidazole-1-yl)-propanhydroxyiminoamide (N2IPA) as a tumor hypoxia marker,” Nuclear Medicine and Biology, vol. 31, no. 2, pp. 199–203, 2004.
- B. M. Seddon, R. J. Maxwell, D. J. Honess et al., “Validation of the fluorinated 2-nitroimidazole SR-4554 as a noninvasive hypoxia marker detected by magnetic resonance spectroscopy,” Clinical Cancer Research, vol. 8, no. 7, pp. 2323–2335, 2002.
- L. Bentzen, S. Keiding, M. Nordsmark et al., “Tumour oxygenation assessed by 18F-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours,” Radiotherapy and Oncology, vol. 67, no. 3, pp. 339–344, 2003.
- T. Grönroos, L. Bentzen, P. Marjamäki et al., “Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 31, no. 4, pp. 513–520, 2004.
- M. B. Mallia, S. Subramanian, A. Mathur, H. D. Sarma, M. Venkatesh, and S. Banerjee, “Comparing hypoxia-targeting potential of 99mTc(CO) 3-labeled 2-nitro and 4-nitroimidazole,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 51, no. 8, pp. 308–313, 2008.
- K. M. Herzog, E. Deutsch, K. Deutsch, E. B. Silberstein, R. Sarangarajan, and W. Cacini, “Synthesis and renal excretion of technetium-99m-labeled organic cations,” Journal of Nuclear Medicine, vol. 33, no. 12, pp. 2190–2195, 1992.
- F. L. Kong, M. S. Ali, Y. Zhang et al., “Synthesis and evaluation of amino acid-based radiotracer -N4-AMT for breast cancer imaging,” Journal of Biomedicine and Biotechnology, vol. 2011, Article ID 276907, 7 pages, 2011.
- S. Liu, “The role of coordination chemistry in the development of target-specific radiopharmaceuticals,” Chemical Society Reviews, vol. 33, no. 7, pp. 445–461, 2004.
- S. Liu, “Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides,” Advanced Drug Delivery Reviews, vol. 60, no. 12, pp. 1347–1370, 2008.
- K. Ohtsuki, K. Akashi, Y. Aoka et al., “Technetium-99m HYNIC-annexin V: a potential radiopharmaceutical for the in-vivo detection of apoptosis,” European Journal of Nuclear Medicine, vol. 26, no. 10, pp. 1251–1258, 1999.
- C. G. Van Nerom, G. M. Bormans, M. J. De Roo, and A. M. Verbruggen, “First experience in healthy volunteers with technetium-99m L,L-ethylenedicysteine, a new renal imaging agent,” European Journal of Nuclear Medicine, vol. 20, no. 9, pp. 738–746, 1993.
- C. H. Kao, S. P. ChangLai, P. U. Chieng, and T. C. Yen, “Technicium-99m methoxyisobutylisonitrile chest imaging of a small cell lung carcinoma: relation to patient prognosis and chemotherapy response- a preliminary report,” Cancer, vol. 83, pp. 64–68, 1998.
- H. C. Wu, C. H. Chang, M. M. Lai, C. C. Lin, C. C. Lee, and A. Kao, “Using Tc-99m DMSA renal cortex scan to detect renal damage in women with type 2 diabetes,” Journal of Diabetes and Its Complications, vol. 17, no. 5, pp. 297–300, 2003.
- J. M. Brown and A. J. Giaccia, “The unique physiology of solid tumors: opportunities (and problems) for cancer therapy,” Cancer Research, vol. 58, no. 7, pp. 1408–1416, 1998.
- H. Y. Lee, T. Lee, N. Lee et al., “Src activates HIF-1α not through direct phosphorylation of HIF-1α-specific prolyl-4 hydroxylase 2 but through activation of the NADPH oxidase/Rac pathway,” Carcinogenesis, vol. 32, no. 5, pp. 703–712, 2011.